Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial

BACKGROUND: The EXAMINE trial tested the efficacy and safety of alogliptin, an inhibitor of dipeptidyl peptidase 4, compared with placebo in 5380 patients with type 2 diabetes and a recent acute coronary syndrome. Because alogliptin is cleared by the kidney, patients were stratified according to scr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, João Pedro, Mehta, Cyrus, Sharma, Abhinav, Nissen, Steven E., Rossignol, Patrick, Zannad, Faiez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271537/
https://www.ncbi.nlm.nih.gov/pubmed/32493335
http://dx.doi.org/10.1186/s12916-020-01616-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271537/
https://www.ncbi.nlm.nih.gov/pubmed/32493335
http://dx.doi.org/10.1186/s12916-020-01616-8

Ejemplares similares